Literature DB >> 26301603

Effect of Discontinuation of Antihypertensive Treatment in Elderly People on Cognitive Functioning--the DANTE Study Leiden: A Randomized Clinical Trial.

Justine E F Moonen1, Jessica C Foster-Dingley1, Wouter de Ruijter2, Jeroen van der Grond3, Anne Suzanne Bertens4, Mark A van Buchem3, Jacobijn Gussekloo2, Huub A Middelkoop5, Marieke J H Wermer6, Rudi G J Westendorp7, Anton J M de Craen8, Roos C van der Mast9.   

Abstract

IMPORTANCE: Observational studies indicate that lower blood pressure (BP) increases risk for cognitive decline in elderly individuals. Older persons are at risk for impaired cerebral autoregulation; lowering their BP may compromise cerebral blood flow and cognitive function.
OBJECTIVE: To assess whether discontinuation of antihypertensive treatment in older persons with mild cognitive deficits improves cognitive, psychological, and general daily functioning. DESIGN, SETTING, AND PARTICIPANTS: A community-based randomized clinical trial with a blinded outcome assessment at the 16-week follow-up was performed at 128 general practices in the Netherlands. A total of 385 participants 75 years or older with mild cognitive deficits (Mini-Mental State Examination score, 21-27) without serious cardiovascular disease who received antihypertensive treatment were enrolled in the Discontinuation of Antihypertensive Treatment in Elderly People (DANTE) Study Leiden from June 26, 2011, through August 23, 2013 (follow-up, December 16, 2013). Intention-to-treat analyses were performed from January 20 through April 11, 2014.
INTERVENTIONS: Discontinuation (n=199) vs continuation (n=186) of antihypertensive treatment (allocation ratio, 1:1). MAIN OUTCOMES AND MEASURES: Change in the overall cognition compound score. Secondary outcomes included changes in scores on cognitive domains, the Geriatric Depression Scale-15, Apathy Scale, Groningen Activity Restriction Scale (functional status), and Cantril Ladder (quality of life).
RESULTS: Compared with 176 participants undergoing analysis in the control (continuation) group, 180 in the intervention (discontinuation) group had a greater increase (95% CI) in systolic BP (difference, 7.36 [3.02 to 11.69] mm Hg; P=.001) and diastolic BP (difference, 2.63 [0.34 to 4.93] mm Hg; P=.03). The intervention group did not differ from the control group in change (95% CI) in overall cognition compound score (0.01 [-0.14 to 0.16] vs -0.01 [-0.16 to 0.14]; difference, 0.02 [-0.19 to 0.23]; P=.84). The intervention and control groups did not differ significantly in secondary outcomes, including differences (95% CIs) in change in compound scores of the 3 cognitive domains (executive function, -0.07 [-0.29 to 0.15; P=.52], memory, 0.08 [-0.12 to 0.29; P=.43], and psychomotor speed, -0.85 [-1.72 to 0.02; P=.06]), symptoms of apathy (0.17 [-0.65 to 0.99; P=.68]) and depression (0.14 [-0.20 to 0.48; P=.41]), functional status (-0.72 [-1.52 to 0.09; P=.08]), and quality-of-life score (-0.09 [-0.34 to 0.16; P=.46]). Adverse events were equally distributed. CONCLUSIONS AND RELEVANCE: In older persons with mild cognitive deficits, discontinuation of antihypertensive treatment did not improve cognitive, psychological, or general daily functioning at the 16-week follow-up. TRIAL REGISTRATION: trialregister.nl Identifier: NTR2829.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26301603     DOI: 10.1001/jamainternmed.2015.4103

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  42 in total

Review 1.  Going Beyond the Guidelines in Individualising the Use of Antihypertensive Drugs in Older Patients.

Authors:  Ian A Scott; Sarah N Hilmer; David G Le Couteur
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

2.  The Pharmacological Treatment of Arterial Hypertension in Frail, Older Patients—a Systematic Review

Authors:  Viktoria Mühlbauer; Dhayana Dallmeier; Simone Brefka; Claudia Bollig; Sebastian Voigt-Radloff; Michael Denkinger
Journal:  Dtsch Arztebl Int       Date:  2019-01-18       Impact factor: 5.594

Review 3.  Deprescribing in Older Adults With Cardiovascular Disease.

Authors:  Ashok Krishnaswami; Michael A Steinman; Parag Goyal; Andrew R Zullo; Timothy S Anderson; Kim K Birtcher; Sarah J Goodlin; Mathew S Maurer; Karen P Alexander; Michael W Rich; Jennifer Tjia
Journal:  J Am Coll Cardiol       Date:  2019-05-28       Impact factor: 24.094

Review 4.  Hypertension Management in Nursing Homes: Review of Evidence and Considerations for Care.

Authors:  Michelle Vu; Loren J Schleiden; Michelle L Harlan; Carolyn T Thorpe
Journal:  Curr Hypertens Rep       Date:  2020-01-14       Impact factor: 5.369

5.  Systolic Blood Pressure and Cognitive Decline in Older Adults With Hypertension.

Authors:  Sven Streit; Rosalinde K E Poortvliet; Wendy P J den Elzen; Jeanet W Blom; Jacobijn Gussekloo
Journal:  Ann Fam Med       Date:  2019-03       Impact factor: 5.166

6.  Does Deprescribing Improve Quality of Life? A Systematic Review of the Literature.

Authors:  Jennifer A Pruskowski; Sydney Springer; Carolyn T Thorpe; Michele Klein-Fedyshin; Steven M Handler
Journal:  Drugs Aging       Date:  2019-12       Impact factor: 3.923

Review 7.  A practical approach to the pharmacological management of hypertension in older people.

Authors:  Nikesh Parekh; Amy Page; Khalid Ali; Kevin Davies; Chakravarthi Rajkumar
Journal:  Ther Adv Drug Saf       Date:  2016-12-27

8.  Blood pressure evaluation and review of antihypertensive medication in patients with life limiting illness.

Authors:  Felicity Dewhurst; Lisa Baker; Inga Andrew; Adam Todd
Journal:  Int J Clin Pharm       Date:  2016-06-24

9.  Influence of Small Vessel Disease and Microstructural Integrity on Neurocognitive Functioning in Older Individuals: The DANTE Study Leiden.

Authors:  J E F Moonen; J C Foster-Dingley; A A van den Berg-Huijsmans; W de Ruijter; A J M de Craen; J van der Grond; R C van der Mast
Journal:  AJNR Am J Neuroradiol       Date:  2016-09-22       Impact factor: 3.825

10.  Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial.

Authors:  Marco Proietti; Valeria Raparelli; Brian Olshansky; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2015-11-02       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.